Explore

Cerevance Parkinson's Drug Solengepras Shows Promise in Phase 3 Trial, Paving Way for FDA Discussions

Cerevance Parkinson's Drug Solengepras Shows Promise in Phase 3 Trial, Paving Way for FDA Discussions

Cerevance, a neuroscience spinout from Takeda, announced that its Parkinson’s disease therapy, solengepras, successfully met its primary endpoint in a late-stage clinical trial. The Phase 3 ARISE trial demonstrated that a high 150-mg dose of solengepras significantly reduced daily 'off time'—periods when standard Parkinson's drugs wear off and symptoms return—by 0.61 hours compared to placebo at week 12. This benefit was observed as early as the second week of treatment. Additionally, the therapy increased 'on time' without difficult symptoms like dyskinesia, which are involuntary, erratic movements associated with Parkinson’s. The study also noted improvements in daytime sleepiness and overall quality of life, suggesting broad motor and non-motor benefits. The ARISE study involved 341 Parkinson's patients experiencing motor fluctuations with standard levodopa and other medications. At baseline, patients averaged 5.65 hours of off time daily, which dropped by 1.56 hours in the 150-mg solengepras group vers...

Arboretum LifeSciences Launches with $30 Million Series A to Advance Precision Medicine for Common Diseases

Arboretum LifeSciences Launches with $30 Million Series A to Advance Precision Medicine for Common Diseases

Arboretum LifeSciences Launches with $30 Million Series A to Advance Precision Medicine for Common Diseases

FDA Maintains Hold on Newron's Schizophrenia Drug Trial Following Multiple Patient Deaths

FDA Maintains Hold on Newron's Schizophrenia Drug Trial Following Multiple Patient Deaths

The U.S. Food and Drug Administration (FDA) is maintaining a hold on Newron Pharmaceuticals' Phase 3 ENIGMA-TRS 2 trial for evenamide, an investigational schizophrenia drug. This decision follows the revelation of four patient deaths among those receiving evenamide across all clinical studies, with a fifth death occurring in the placebo group. The FDA initially placed a hold on the trial in April after one patient death, which Newron had deemed unrelated to the drug. The agency's concern stems from evenamide's mechanism of action as a selective voltage-gated sodium channel blocker, a class of drugs that can potentially cause irregular heartbeats and serious cardiovascular events or seizures. Newron states that three of the four deaths in the investigational group are considered unrelated to the treatment, while one death's cause remains undetermined, making it 'possibly related.' The company is currently reviewing the FDA's feedback and all safety data, including over 10,000 ECGs from approximately 700 pat...

Arboretum LifeSciences Secures $30 Million Series A Funding to Advance Genomic Medicine

Arboretum LifeSciences Secures $30 Million Series A Funding to Advance Genomic Medicine

Arboretum LifeSciences Secures $30 Million Series A Funding to Advance Genomic Medicine

AMO Pharma Receives FDA Advice on Phase 3 Trial Design for AMO-02 in Arrhythmogenic Cardiomyopathy Treatment

AMO Pharma Receives FDA Advice on Phase 3 Trial Design for AMO-02 in Arrhythmogenic Cardiomyopathy Treatment

AMO Pharma Receives FDA Advice on Phase 3 Trial Design for AMO-02 in Arrhythmogenic Cardiomyopathy Treatment

AI Transforms Clinical Trials with Enhanced Imaging Analysis and Patient Selection

AI Transforms Clinical Trials with Enhanced Imaging Analysis and Patient Selection

Artificial intelligence is revolutionizing clinical trials by significantly improving the speed, standardization, and objectivity of medical imaging analysis. Traditionally, radiologists manually review images like MRI, CT, and PET scans, a process that is time-consuming and prone to variability. AI-driven tools, utilizing deep learning and computer vision, can detect subtle changes in disease progression that are often difficult for humans to quantify. This advancement is leading to faster decision-making in drug development, with industry reports indicating AI can accelerate imaging review timelines by up to 50%. Regulatory agencies are increasingly receptive to AI in clinical trials, provided the tools are properly validated, as AI provides clear, quantifiable evidence crucial for submissions. Beyond imaging, AI is also being used to broaden clinical trial screening and is integrated into adaptive clinical trial designs. The FDA has established the Office of Innovation and Clinical Trial Modernization t...

AI-Enabled Tools Revolutionize Clinical Trial Feasibility, Moving it Upstream in Protocol Development

AI-Enabled Tools Revolutionize Clinical Trial Feasibility, Moving it Upstream in Protocol Development

Artificial Intelligence (AI)-enabled tools are fundamentally changing how clinical trial feasibility is conducted, shifting it from a retrospective validation step to an ongoing, iterative part of protocol development. Traditionally, feasibility studies were performed late in the process, after a protocol was largely finalized, leading to delays and costly amendments if assumptions about cohort sizes, outcome rates, or eligibility criteria proved incorrect. AI tools, such as those offered by TriNetX, now allow study teams to evaluate assumptions against real-world data (RWD) continuously as criteria are being set. This is made possible by natural language interfaces that enable users to enter eligibility criteria in plain language, which the system then translates into clinical code sets to generate patient counts instantly. For example, adjusting a single BMI exclusion criterion in a type 2 diabetes query can change the cohort size by thousands of patients in real-time, providing immediate visual feedback...

GLP-1 Medications Show Potential to Slow Biological Aging Markers, According to New Research

GLP-1 Medications Show Potential to Slow Biological Aging Markers, According to New Research

Emerging research suggests that GLP-1 medications, widely known for weight loss, may also influence biological markers associated with aging. Findings from Novo Nordisk and Eli Lilly, presented at the Aging Research & Drug Development conference in Boston, indicate that these drugs could slow some of these aging markers. Researchers utilize biological aging clocks, which analyze molecular changes like DNA methylation, to estimate the body's aging pace. One study on semaglutide, the active ingredient in Ozempic and Wegovy, showed slower epigenetic aging on several DNA-based aging clocks. Specifically, the DunedinPACE measure indicated an approximately 9% slower pace of biological aging compared to a placebo. Other clocks showed differences equivalent to roughly two to five years of epigenetic aging per year when annualized over 32 weeks. Additionally, favorable changes were observed in aging markers related to inflammation, metabolism, and several organ systems, including the brain, heart, kidneys, and live...

HHS Unveils AI Initiatives to Accelerate U.S. Clinical Trials

HHS Unveils AI Initiatives to Accelerate U.S. Clinical Trials

The U.S. Department of Health and Human Services (HHS) has announced a new program and three complementary projects aimed at significantly speeding up clinical trials through the integration of artificial intelligence (AI), advanced computational models, and real-time analysis. The core initiative, named SURPASS (Simulation-augmented, Real-time Platform Adaptive Seamless Trials), seeks to develop AI-powered platforms that will continuously and adaptively support clinical trial designs. This program includes the creation of a phaseless design engine to simulate trials for faster results with fewer patients, a continuous inference engine for real-time data analysis and trial adaptations, and an agentic AI operations layer to automate startup activities and data collection. These efforts are part of a broader strategy by HHS to transform U.S. clinical trials, building on previous initiatives like Operation TrialBlazer and the FDA's pilot program using AI for real-time clinical trial data monitoring. The goal ...

Vagus Nerve Stimulation Shows Promise in Myelin Repair for Multiple Sclerosis Patients

Vagus Nerve Stimulation Shows Promise in Myelin Repair for Multiple Sclerosis Patients

Neuroscientist Cristin Welle, PhD, and her team at CU Anschutz have discovered that vagus nerve stimulation (VNS) may promote myelin regrowth in individuals with multiple sclerosis (MS). This research, initially conducted on animal models and subsequently in a small human pilot study, has shown promising results, leading to a phased National Institutes of Health grant to further their work. The studies indicated a notable increase in new oligodendrocytes, which are cells responsible for producing myelin, the protective coating around nerve fibers that is damaged in MS. Furthermore, brain images suggested that the regenerated myelin in animal models was returning to its original locations, a phenomenon referred to as myelin pattern recovery, which is linked to improvements in motor function. This approach draws parallels from the successful application of VNS in stroke rehabilitation, where electrical bursts stimulate brain cell regeneration.

Soda Steel Gummies Marketed for Male Vitality Lack Clinical Trial Evidence

Soda Steel Gummies Marketed for Male Vitality Lack Clinical Trial Evidence

Soda Steel Gummies Marketed for Male Vitality Lack Clinical Trial Evidence

Kyverna Therapeutics Nears Market with CAR T Therapy for Autoimmune Disease Amid Safety Concerns for Competitors

Kyverna Therapeutics Nears Market with CAR T Therapy for Autoimmune Disease Amid Safety Concerns for Competitors

Kyverna Therapeutics is advancing its CAR T-cell therapy, mivocabtagene autoleucel (miv-cel), towards market approval for stiff person syndrome (SPS), a rare autoimmune neurological disease. This progress comes as competitors Novartis and Bristol Myers Squibb (BMS) have paused their autoimmune CAR T trials due to significant safety concerns, including patient deaths and inflammatory events. Kyverna recently reported positive one-year durability data from its Phase 2 KYSA-8 trial, showing miv-cel improved mobility and leg function in 26 SPS patients with a solid safety profile, notably without high-grade cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), or immune effector cell-associated hemophagocytic lymphohistiocytosis–like syndrome (IEC-HS). Novartis's rap-cel was linked to three patient deaths from IEC-HS, while BMS observed 'transient and reversible inflammatory events' with its zolacabtagene autoleucel (zola-cel). Kyverna attributes miv-cel's safety to i...